Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 13, 2024 07:00 ET | Source: Voyager Therapeutics, Inc.

Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer

LEXINGTON, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment...
February 28, 2024 16:01 ET | Source: Voyager Therapeutics, Inc.

Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results

- Company had approximately $431 million in pro-forma cash as of December 31, 2023, adjusted for $100 million consideration from Novartis agreements and $100 million public offering - - Strong cash...
February 26, 2024 07:00 ET | Source: Voyager Therapeutics, Inc.

Voyager Therapeutics Announces Selection of Gene Therapy Development Candidate for Friedreich’s Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment

LEXINGTON, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the joint...
February 21, 2024 07:00 ET | Source: Voyager Therapeutics, Inc.

Voyager Therapeutics Announces Fourth Quarter 2023 Conference Call and Webcast

LEXINGTON, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report...
February 20, 2024 07:00 ET | Source: Voyager Therapeutics, Inc.

Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer’s Disease and Advances Program into Late Research

- Additional new data demonstrate VY-TAU01, Voyager’s lead antibody targeting pathological tau, was well-tolerated and demonstrated favorable pharmacokinetics in non-human primates (NHPs) - - Data to...
February 07, 2024 07:00 ET | Source: Voyager Therapeutics, Inc.

Voyager Therapeutics to Present at the Oppenheimer Annual Life Sciences Conference

LEXINGTON, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that Chief...
January 04, 2024 22:45 ET | Source: Voyager Therapeutics, Inc.

Voyager Therapeutics Announces Pricing of Public Offering

LEXINGTON, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the pricing of...
January 04, 2024 16:14 ET | Source: Voyager Therapeutics, Inc.

Voyager Therapeutics Announces Proposed Public Offering

LEXINGTON, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that it has...
January 03, 2024 07:00 ET | Source: Voyager Therapeutics, Inc.

Voyager Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

LEXINGTON, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that Chief...
January 02, 2024 07:00 ET | Source: Voyager Therapeutics, Inc.

Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Advance Novel Gene Therapies

- Collaboration with gene therapy leader Novartis aims to discover and develop new approaches for Huntington’s disease and spinal muscular atrophy - - Voyager to receive up-front consideration of...